EcoR1 Capital LLC Takes $4.49 Million Position in Evolus, Inc. $EOLS

EcoR1 Capital LLC acquired a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 675,000 shares of the company’s stock, valued at approximately $4,489,000. Evolus accounts for about 0.2% of EcoR1 Capital LLC’s holdings, making the stock its 24th largest position.

Several other hedge funds have also recently made changes to their positions in EOLS. Braidwell LP purchased a new position in shares of Evolus during the fourth quarter valued at approximately $20,650,000. Nantahala Capital Management LLC raised its holdings in shares of Evolus by 33.2% during the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock valued at $35,163,000 after purchasing an additional 1,428,931 shares during the last quarter. Soleus Capital Management L.P. raised its holdings in shares of Evolus by 96.4% during the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after purchasing an additional 1,039,842 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Evolus during the fourth quarter valued at approximately $6,490,000. Finally, Caligan Partners LP raised its holdings in shares of Evolus by 23.8% during the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Trading Up 1.7%

Shares of NASDAQ EOLS opened at $6.74 on Thursday. The firm has a 50 day moving average of $5.87 and a 200 day moving average of $5.55. The firm has a market capitalization of $443.90 million, a price-to-earnings ratio of -10.06 and a beta of 1.34. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $10.20.

Evolus (NASDAQ:EOLS) last announced its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same period last year, the business earned ($0.30) EPS. Sell-side analysts predict that Evolus, Inc. will post -0.38 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on EOLS shares. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a report on Wednesday. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Evolus presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 13,669 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $4.75, for a total transaction of $64,927.75. Following the completion of the sale, the insider directly owned 604,700 shares in the company, valued at approximately $2,872,325. The trade was a 2.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.00% of the company’s stock.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.